Sunbelt Securities Inc. Takes $260,000 Position in Stryker Co. (NYSE:SYK)

Share on StockTwits

Sunbelt Securities Inc. purchased a new stake in Stryker Co. (NYSE:SYK) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 1,201 shares of the medical technology company’s stock, valued at approximately $260,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Parametric Portfolio Associates LLC grew its position in shares of Stryker by 2.3% in the third quarter. Parametric Portfolio Associates LLC now owns 1,027,882 shares of the medical technology company’s stock valued at $222,331,000 after purchasing an additional 22,698 shares in the last quarter. California State Teachers Retirement System grew its position in shares of Stryker by 1.2% in the third quarter. California State Teachers Retirement System now owns 580,523 shares of the medical technology company’s stock valued at $125,567,000 after purchasing an additional 6,712 shares in the last quarter. Pacitti Group Inc. purchased a new position in shares of Stryker in the third quarter valued at $426,000. Ancora Advisors LLC grew its position in shares of Stryker by 45.8% in the third quarter. Ancora Advisors LLC now owns 2,857 shares of the medical technology company’s stock valued at $618,000 after purchasing an additional 897 shares in the last quarter. Finally, Andra AP fonden grew its position in shares of Stryker by 1.4% in the third quarter. Andra AP fonden now owns 28,000 shares of the medical technology company’s stock valued at $6,056,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 73.22% of the company’s stock.

In other news, VP M Kathryn Fink sold 28,690 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $220.97, for a total value of $6,339,629.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Timothy J. Scannell sold 4,666 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $218.51, for a total value of $1,019,567.66. The disclosure for this sale can be found here. Insiders sold a total of 67,174 shares of company stock valued at $14,606,285 over the last quarter. Company insiders own 7.20% of the company’s stock.

SYK opened at $204.86 on Monday. The stock has a 50-day moving average price of $208.39 and a 200-day moving average price of $207.25. Stryker Co. has a 12-month low of $144.75 and a 12-month high of $223.45. The company has a current ratio of 2.18, a quick ratio of 1.35 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $76.64 billion, a P/E ratio of 28.02, a PEG ratio of 2.51 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.90 by $0.01. Stryker had a return on equity of 25.33% and a net margin of 23.55%. The firm had revenue of $3.59 billion during the quarter, compared to analysts’ expectations of $3.58 billion. During the same period in the prior year, the business earned $1.69 EPS. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities research analysts predict that Stryker Co. will post 8.23 EPS for the current year.

SYK has been the subject of several recent research reports. Zacks Investment Research upgraded Stryker from a “hold” rating to a “buy” rating and set a $215.00 price target for the company in a research report on Thursday. ValuEngine cut Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies restated a “buy” rating on shares of Stryker in a research report on Wednesday, September 4th. Canaccord Genuity boosted their target price on Stryker from $233.00 to $240.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, BTIG Research set a $228.00 target price on Stryker and gave the stock a “buy” rating in a research report on Thursday, September 5th. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $218.19.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.